Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
AffyImmune Receives FDA RMAT Designation for AIC100 in Recurrent Anaplastic Thyroid Cancer
Details : AIC100, an ICAM-1 targeting and affinity-tuned LFA-1 binder CAR T-cell therapy. Currently, it is being evaluated for the treatment of patients with recurrent anaplastic thyroid cancer.
Brand Name : AIC100
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
July 23, 2024
AffyImmune Therapeutics Announces $30M Series A+ Financing from ORI Capital
Details : The funding will be used to advance the Phase 1 study of AffyImmune’s lead asset, AIC100, for the treatment of anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer.
Brand Name : AIC100
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 07, 2021
Lead Product(s) : AIC100
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Weill Cornell Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer
Details : The FDA's Fast Track designation is designed for AIC100 facilitate development and expedite review of drug candidates to treat serious conditions and address an unmet medical need.
Brand Name : AIC100
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 17, 2021
Lead Product(s) : AIC100
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Weill Cornell Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The study is being conducted at Weill Cornell Medicine. Unlike most CAR-T cell products, AIC100 was designed to specifically target tumor cells overexpressing the target (ICAM-1) while avoiding normal cells expressing lower levels.
Brand Name : AIC100
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 29, 2020
LOOKING FOR A SUPPLIER?
Reset All
